Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model

Vaccine

Volumn 20, Issue 29-30, 2002, Pages 3523-3531

  Dargeviciute, Ausra ^a   Brus Sjölander, Katarina ^b,c   Sasnauskas, Kestutis ^a   Krüger, Detlev H ^d   Meisel, Helga ^d   Ulrich, Rainer ^d   Lundkvist, Åke ^b,c  

^a VILNIUS UNIVERSITY   (Lithuania)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bank vole; Hantavirus; Puumala virus; Vaccine; Yeast expressed nucleocapsid protein

Indexed keywords

FREUND ADJUVANT; MONOCLONAL ANTIBODY; NUCLEOCAPSID PROTEIN; RECOMBINANT VACCINE; VIRUS PROTEIN; VIRUS RNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGENICITY; ARTICLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DISEASE MODEL; GENE SEQUENCE; GENETIC CODE; HANTAVIRUS; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUUMALA VIRUS; RODENT DISEASE; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION; VOLE; YEAST;

ANIMALS; ANTIBODIES, VIRAL; ARVICOLINAE; HUMANS; MODELS, ANIMAL; NUCLEOCAPSID PROTEINS; PUUMALA VIRUS; SACCHAROMYCES CEREVISIAE; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0037019880     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00341-9     Document Type: Article

References (46)

1. Plyusnin A., Krüger D.H., Lundkvist Å. Hantavirus infections in Europe. Adv. Virus Res. 57:2001;105-136.
2. Johnson K.M. Hantaviruses: history and overview. Curr. Top. Microbiol. Immunol. 256:2001;1-14.
3. Krüger D.H., Ulrich R., Lundkvist Å. Hantavirus infections and their prevention. Microbes Infect. 3:2001;1129-1144.
4. Avsic-Zupanc T., Petrovec M., Kapš R., Elgh F., Lundkvist Å. Hemorrhagic fever with renal syndrome in the Dolenjska region of Slovenia - a 10-year survey. Clin. Infect. Dis. 28:1999;860-865.
5. Meisel H., Lundkvist Å., Gantzer K., Bär W., Sibold C., Krüger D.H. First case of infection by hantavirus Dobrava in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 17:1998;884-892.
6. Avsic-Zupanc T., Nemirov K., Petrovec M.et al. Genetic analysis of wild-type Dobrava hantavirus in Slovenia: co-existence of two distinct genetic lineages within the same natural focus. J. Gen. Virol. 81:2000;1747-1755.
7. Golovljova I., Vasilenko V., Prükk T., Brus Sjölander K., Plyusnin A., Lundkvist Å. Puumala and Dobrava hantaviruses causing hemorrhagic fever with renal syndrome in Estonia. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;968-969.
8. Sibold C., Meisel H., Lundkvist Å.et al. Simultaneous occurrence of Dobrava, Puumala, and Tula hantaviruses in Slovakia. Am. J. Trop. Med. Hyg. 61:1999;409-411.
9. Sibold C., Ulrich R., Labuda M.et al. Dobrava hantavirus causes hemorrhagic fever with renal syndrome in central Europe and is carried by two different Apodemus mice species. J. Med. Virol. 63:2001;158-167.
10. Schütt M., Gerke P., Meisel H., Ulrich R., Krüger D.H. Clinical characterization of Dobrava hantavirus infections in Germany. Clin. Nephrol. 55:2001;371-374.
11. Brus Sjölander K., Golovljova I., Vasilenko V., Plyusnin A., Lundkvist Å. Serological divergence of Dobrava and Saaremaa hantaviruses: evidence for two distinct serotypes. Epidemiol. Infect. 128:2002;99-103.
12. Heyman P., Vervoort T., Colson P., Chu Y.K., Avsic-Zupanc T., Lundkvist Å. A major outbreak of hantavirus infection in Belgium in 1995 and 1996. Epidemiol. Infect. 122:1999;447-453.
13. Meyer B.J., Schmaljohn C.S. Persistent hantavirus infections: characteristics and mechanisms. Trends Microbiol. 8:2000;61-67.
14. Hooper J.W., Custer D.M., Thompson E., Schmaljohn C.S. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys. J. Virol. 75:2001;8469-8477.
15. Schmaljohn C.S., Chu Y.K., Schmaljohn A.L., Dalrymple J.M. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J. Virol. 64:1990;3162-3170.
16. Yoshimatsu K., Yoo Y.C., Yoshida R., Ishihara C., Azuma I., Arikawa J. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch. Virol. 130:1993;365-376.
17. Lundkvist Å., Kallio-Kokko H., Brus Sjölander K.et al. Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology. 216:1996;397-406.
18. Schmaljohn C.S., Hasty S.E., Dalrymple J.M. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine. 10:1992;10-13.
19. Chu Y.K., Jennings G.B., Schmaljohn C.S. A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J. Virol. 69:1995;6417-6423.
20. McClain D.J., Summers P.L., Harrison S.A., Schmaljohn A.L., Schmaljohn C.S. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol. 60:2000;77-85.
21. Ulrich R., Lundkvist Å., Meisel H.et al. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine. 16:1998;272-280.
22. Ulrich R., Koletzki D., Lachmann S.et al. New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J. Biotechnol. 73:1999;141-153.
23. Koletzki D., Lundkvist Å., Brus Sjölander K.et al. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology. 276:2000;364-375.
24. Kamrud K.I., Hooper J.W., Elgh F., Schmaljohn C.S. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology. 263:1999;209-219.
25. Hooper J.W., Kamrud K.I., Elgh F., Custer D.M., Schmaljohn C.S. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology. 255:1999;269-278.
26. Schmaljohn C, Kamrud K, Hooper J. Recombinant DNA vaccines for hantaviruses. In: Saluzzo JE, Dodes B, editors. Factors in the Emergence and Control of Rodent-borne Viral Diseases (Hantaviral and Arenaviral Diseases). Amsterdam: Elsevier; 1999. p. 163-73.
27. Bucht G., Brus Sjölander K., Eriksson S., Lindgren L., Lundkvist Å., Elgh F. Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. Vaccine. 19:2001;3820-3829.
28. Xu X., Ruo S.L., McCormick J.B., Fisher-Hoch S.P. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am. J. Trop. Med. Hyg. 47:1992;397-404.
29. Sasnauskas K., Buzaite O., Vogel F.et al. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol. Chem. 380:1999;381-386.
30. Reip A., Haring B., Sibold C.et al. Coding strategy of the S and M genomic segments of a hantavirus representing a new subtype of the Puumala serotype. Arch. Virol. 140:1995;2011-2026.
31. Cifire F. Expression und immunologische Charakterisierung des Nukleokapsidproteins vom Hantavirusisolat Vranica. Ph.D. thesis, Free University Berlin; 1997.
32. Montenecourt B.S., Kuo S.C., Lampen J.O. Saccharomyces mutants with invertase formation resistant to repression hexoses. J. Bacteriol. 114:1973;233-238.
33. Lundkvist Å., Fatouros A., Niklasson B. Antigenic variation of European haemorrhagic fever with renal syndrome virus strains characterized using bank vole monoclonal antibodies. J. Gen. Virol. 72:1991;2097-2103.
34. Zöller L.G., Yang S., Gött P., Bautz E.K.F., Darai G. A novel μ-capture enzyme-linked immunosorbent assay based on recombinant proteins for sensitive and specific diagnosis of hemorrhagic fever with renal syndrome. J. Clin. Microbiol. 31:1993;1194-1199.
35. Lundkvist Å., Cheng Y., Brus Sjölander K., Niklasson B., Vaheri A., Plyusnin A. Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment. J. Virol. 71:1997;9515-9523.
36. Plyusnin A., Hörling J., Kanerva M.et al. Puumala hantavirus genome in patients with nephropathia epidemica: correlation of PCR positivity with HLA haplotype and link to viral sequences in local rodents. J. Clin. Microbiol. 35:1997;1090-1096.
37. Klingström J., Plyusnin A., Vaheri A., Lundkvist Å. Wild-type Puumala hantavirus infection induces cytokines, c-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J. Virol. 76:2002;444-449.
38. Lundkvist Å., Niklasson B. Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins; identification of epitopes involved in neutralization. Arch. Virol. 126:1992;93-105.
39. Lundkvist Å., Vapalahti O., Plyusnin A., Brus Sjölander K., Niklasson B., Vaheri A. Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed nucleocapsid protein. Virus Res. 45:1996;29-44.
40. Hörling J., Lundkvist Å., Jaarola M.et al. Distribution and genetic heterogeneity of Puumala virus in Sweden. J. Gen. Virol. 77:1996;2555-2562.
41. Lundkvist Å., Hörling J., Björsten S., Niklasson B. Sensitive detection of hantaviruses by biotin-streptavidin enhanced immunoassays based on bank vole monoclonal antibodies. J. Virol. Methods. 52:1995;75-86.
42. Lundkvist Å., Meisel H., Koletzki D.et al. Mapping of B-cell epitopes in the nucleocapsid protein of Puumala hantavirus. Viral Immunol. 15:2002;177-192.
43. Vapalahti O., Lundkvist Å., Kallio-Kokko H.et al. Antigenic properties and diagnostic potential of Puumala virus nucleocapsid protein expressed in insect cells. J. Clin. Microbiol. 34:1996;119-125.
44. Elgh F., Lundkvist Å., Alexeyev O.A., Wadell G., Juto P. A major antigenic domain for the human humoral response to Puumala virus nucleocapsid protein is located at the amino-terminus. J. Virol. Methods. 59:1996;161-172.
45. ®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 126:2001;135-139.
46. de Carvalho Nicacio C., Sällberg M., Hultgren C., Lundkvist Å. T-helper and humoral responses to Puumala hantavirus nucelocapsid protein: identification of T-helper epitopes in a mouse model. J. Gen. Virol. 82:2001;129-138.